Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens

Colaboración

Año: 2023

Podzamczer, D; Imaz, A; Lopez-Lirola, A; Knobel, H; Masiá, M; Fanciulli, C; Hernández, C; Lagarde, M; Gutierrez, A; Curran, A; Morano, L; Montero-Alonso, M; Troya, J; Rigo, R; Casadellà, M; Navarro-Alcaraz, A; Ardila, F; Parera, M; Bernal, E; Echeverria,

Título: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

• Q2